Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Mr Kan Stresses Need for Strong Economy, Strong Finance, and Strong Social Security
June 21, 2010
- NDA Review Period Drastically Shortened in FY2009: PMDA
June 21, 2010
- New c-Met Inhibitor Prolongs PFS in PII for NSCLC
June 21, 2010
- ASCO, FDA Open “Expanded Access”Website on Use of Unapproved Drugs
June 21, 2010
- T-DM1 + Pertuzumab Effective for HER2-Positive Breast Cancer
June 21, 2010
- Benefit-Sharing Based on CBD May Affect Pharma Industry
June 21, 2010
- Roche's Hedgehog Inhibitor Safe in Combination with Standard Chemotherapy
June 21, 2010
- Korosho Issues Memo to Clarify Requirements for Applicants
June 21, 2010
- Avastin Prolongs PFS, but Not OS in PIII in Stomach Cancer
June 21, 2010
- DSP Applies for Changes in Maximum Daily Dose for Meropen
June 21, 2010
- Avastin Effective for HER2-Negative Breast Cancer in Japanese Patients
June 21, 2010
- Add Prevenar to Routine Vaccination Programs in Japan: Mr Kindler
June 21, 2010
- Eribulin Receives Priority Review Status in the US
June 21, 2010
- Erbitux + FOLFIRI Effective for Stomach Cancer in PII
June 21, 2010
- Astellas Successfully Completes Tender Offer for OSI
June 14, 2010
- Rohto: Increases in Sales for 17 Straight Years
June 14, 2010
- Falco SD Aims at Sales of ¥70.0 Bil. in FY2013
June 14, 2010
- Banyu Aims at 16% Market Share for Cosopt
June 14, 2010
- Sanofi-aventis Nichi-Iko to Consider Marketing of Authorized Generics
June 14, 2010
- Transnasal GLP-1 Improves Blood Glucose Control
June 14, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…